Short answer: Cagrilintide is a long-acting amylin analogue that acts as an amylin receptor agonist; semaglutide is a GLP-1 receptor agonist. They target distinct receptor systems with complementary mechanisms. Semaglutide is FDA-approved for type 2 diabetes (Ozempic, 2017) and weight management (Wegovy, 2021). Cagrilintide is investigational as of November 2026; the CagriSema combination (cagrilintide plus semaglutide) has completed phase 3 trials and is under FDA review.
Disclosure: This page contains affiliate links. We may earn from qualifying purchases. See our full disclosure.
| Criteria | Cagrilintide | Semaglutide |
|---|---|---|
| Receptor target | Amylin receptor agonist | GLP-1 |
| Endogenous hormone model | Amylin (β-cell co-secreted with insulin) | GLP-1 (incretin from intestinal L-cells) |
| Half-life | 159–195 hours (Enebo 2021) | ~1 week (Ozempic monograph) |
| FDA approval | Not approved (investigational) | Yes (Ozempic 2017, Wegovy 2021) |
| Development stage | Phase 3 monotherapy (RENEW program); combination (CagriSema) filed with FDA | FDA-approved; extensive post-approval data |
| REDEFINE 1 primary endpoint | –20.4% vs –3.0% placebo at wk 68 (CagriSema combination) | Part of CagriSema (cagrilintide + semaglutide) |
| Typical research focus | Amylin receptor pathway research; combination studies | GLP-1 pathway research; FDA-approved comparator |
Cagrilintide and semaglutide activate distinct receptor systems that regulate glucose homeostasis and energy balance through complementary mechanisms. Understanding these differences is critical for research protocol design and institutional procurement decisions.
Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to endogenous human GLP-1. GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by intestinal L-cells in response to nutrient intake. It binds to GLP-1 receptors on pancreatic beta cells, central nervous system neurons, and peripheral tissues.
Mechanism: GLP-1 receptor activation stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon secretion from alpha cells, delays gastric emptying, and reduces appetite through central anorexigenic pathways. Semaglutide has 94% sequence homology to human GLP-1; it incorporates two amino-acid substitutions (Aib at position 8, Arg at position 34) and is derivatised at lysine 26 with a fatty-acid side chain that increases albumin binding, resulting in increased stability against dipeptidyl peptidase-IV (DPP-IV) enzymatic degradation and reduced renal clearance (Lau J et al., J Med Chem 2015, PMID 26308095). These modifications yield an approximately one-week plasma half-life (Ozempic product monograph), enabling once-weekly subcutaneous dosing.
FDA approval and clinical data: Semaglutide is FDA-approved as Ozempic (type 2 diabetes mellitus, approved December 5, 2017; NDA 209637) and Wegovy (chronic weight management, approved June 4, 2021; NDA 215256). The STEP and SUSTAIN phase 3 programs established efficacy in weight management and glycemic control, respectively. The STEP 1 trial (Wilding et al., NEJM 2021, PMID 33567185) demonstrated 14.9% mean weight reduction with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo.
Research-grade availability: Semaglutide is available through research peptide suppliers for laboratory use. Procurement teams should verify batch identity (HPLC and mass spectrometry), purity (HPLC), and endotoxin levels in certificates of analysis. See semaglutide research profile and how to read a peptide COA for quality verification guidance.
Cagrilintide is a long-acting acylated amylin analogue that functions as an amylin receptor agonist. Endogenous amylin (islet amyloid polypeptide, IAPP) is a 37-amino-acid peptide hormone that is colocated and cosecreted with insulin from pancreatic beta cells in response to food intake (SYMLIN prescribing information, section 12.1). Amylin exhibits a high propensity for amyloid fibril formation; pramlintide (a synthetic 37-amino-acid analog of human amylin) is commercially available for diabetes treatment as an adjunct to insulin therapy but requires three daily injections due to its short half-life (Kruse T et al., J Med Chem 2021, PMID 34288673).
Mechanism: Amylin receptor activation slows gastric emptying, suppresses postprandial glucagon secretion, and regulates food intake through centrally mediated modulation of appetite (SYMLIN prescribing information, section 12.1). Cagrilintide is a stable, lipidated long-acting amylin analogue selected through structure-activity relationship work (Kruse et al., J Med Chem 2021). The half-life of cagrilintide ranges from 159 to 195 hours (approximately 7–8 days) (Enebo et al., Lancet 2021, PMID 33894838), supporting once-weekly dosing.
Clinical trial data: Cagrilintide phase 2 monotherapy was evaluated in a 26-week multicenter trial (Lau et al., Lancet 2021, DOI 10.1016/S0140-6736(21)01751-7; PMID 34798060; NCT03856047) in 706 participants with overweight or obesity without diabetes. Mean percentage body-weight changes (trial-product estimand) at week 26 ranged from –6.0% (0.3 mg) to –10.8% (4.5 mg) versus –3.0% with placebo (all doses p<0.001 vs placebo). The 4.5 mg dose: –10.8% vs liraglutide 3.0 mg –9.0% (p=0.03). The most frequent adverse events were gastrointestinal disorders (e.g., nausea, constipation, diarrhoea) and administration-site reactions; gastrointestinal adverse events occurred in 41–63% of cagrilintide recipients versus 32% with placebo.
Regulatory status and compounding prohibition: Cagrilintide is not FDA-approved as of November 16, 2026. It is investigational. The FDA has stated that cagrilintide cannot be used in compounding under federal law; it is not a component of FDA-approved drugs and has not been found safe and effective for any condition (FDA statement on unapproved GLP-1 drugs). Research-grade cagrilintide may be available through specialized suppliers for institutional research use only. Procurement must comply with institutional review board protocols and federal regulations.
CagriSema is the fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, administered once weekly by subcutaneous injection. The rationale for combining amylin and GLP-1 receptor agonism is that these pathways regulate satiety, gastric motility, and glucose homeostasis through distinct receptors.
A phase 1b trial (Enebo et al., Lancet 2021, DOI 10.1016/S0140-6736(21)00845-X; PMID 33894838; NCT03600480) enrolled 96 adults with BMI 27.0–39.9 kg/m² to evaluate concomitant administration of escalating doses of cagrilintide (0.16–4.5 mg) with semaglutide 2.4 mg over 20 weeks. Most adverse events were mild to moderate; 37% of the 566 reported adverse events were gastrointestinal disorders. Cagrilintide exposure was proportional to dose and did not affect semaglutide exposure or elimination. In the exploratory body-weight endpoint at week 20, mean change was −17.1% with cagrilintide 2.4 mg plus semaglutide 2.4 mg versus −9.8% with pooled placebo plus semaglutide 2.4 mg.
A 32-week phase 2 trial (Frias et al., Lancet 2023, DOI 10.1016/S0140-6736(23)01163-7; PMID 37364590; NCT04982575) randomized 92 adults with type 2 diabetes and BMI ≥27 kg/m² to CagriSema, semaglutide, or cagrilintide (all 2.4 mg once weekly) for 32 weeks. Mean HbA1c reduction at week 32 was –2.2 percentage points with CagriSema, –1.8 percentage points with semaglutide, and –0.9 percentage points with cagrilintide. The reduction was greater with CagriSema versus cagrilintide (p<0.0001) but not versus semaglutide (p=0.075). Mean body weight change at week 32 was –15.6% with CagriSema, –5.1% with semaglutide, and –8.1% with cagrilintide; body weight change was greater with CagriSema versus both monotherapies (p<0.0001). Adverse events were predominantly gastrointestinal, mostly mild to moderate.
REDEFINE 1 (Garvey et al., N Engl J Med 2025;393(7):635-647, DOI 10.1056/NEJMoa2502081; PMID 40544433; NCT05567796) was a 68-week phase 3a trial in 3,417 adults with overweight or obesity without diabetes. Participants were randomized to CagriSema (2.4 mg each), semaglutide (2.4 mg), cagrilintide (2.4 mg), or placebo. At week 68, the estimated mean percent change in body weight (treatment-policy estimand) was –20.4% with CagriSema versus –3.0% with placebo (estimated difference –17.3 percentage points; 95% CI –18.1 to –16.6; p<0.001). Proportions achieving body-weight reductions of ≥5%, ≥20%, ≥25%, and ≥30% were all significantly greater with CagriSema versus placebo (p<0.001 for all comparisons). Gastrointestinal adverse events occurred in 79.6% of CagriSema recipients versus 39.9% of placebo recipients, mostly transient and mild-to-moderate.
REDEFINE 2 (Davies et al., N Engl J Med 2025;393(7):648-659, DOI 10.1056/NEJMoa2502082; PMID 40544432; NCT05394519) was a 68-week phase 3a trial in 1,206 adults with type 2 diabetes and BMI ≥27, randomized to CagriSema (2.4 mg each) or placebo. At week 68, estimated mean body-weight change was –13.7% with CagriSema versus –3.4% with placebo (estimated difference –10.4 percentage points; 95% CI –11.2 to –9.5; p<0.001). HbA1c ≤6.5% was achieved by 73.5% of CagriSema recipients versus 15.9% of placebo recipients. Gastrointestinal adverse events occurred in 72.5% of CagriSema recipients versus 34.4% of placebo recipients, mostly transient and mild-to-moderate.
Novo Nordisk submitted a New Drug Application (NDA) for CagriSema to the FDA in December 2025 (Novo Nordisk press release, December 18, 2025). In an October 20, 2026 release, the company said an FDA decision is expected in Q4 2026 (Novo Nordisk, October 20, 2026). As of November 16, 2026, no FDA approval of CagriSema had been announced. Novo Nordisk states that CagriSema is not approved in the US or EU (Novo Nordisk, December 18, 2025).
Both cagrilintide and semaglutide achieve protracted action profiles through fatty acid acylation and reversible albumin binding, yielding once-weekly pharmacokinetics. However, their base peptide sequences, receptor targets, and metabolic pathways differ.
Semaglutide: Molecular weight approximately 4,113.6 Da (Ozempic product monograph). Half-life approximately 1 week (Ozempic product monograph); 145–165 hours for semaglutide 2.4 mg in the Enebo et al. phase 1b trial (Enebo et al., Lancet 2021). Steady state achieved after 4–5 weeks of once-weekly dosing. Metabolism occurs via proteolytic cleavage of the peptide backbone and sequential β-oxidation of the fatty-acid side chain; approximately 3% excreted intact in urine (Ozempic product monograph). See GLP-1 glossary entry and GLP-1 metabolic pathway research guide.
Cagrilintide: Half-life 159–195 hours (Enebo et al., Lancet 2021). Cagrilintide is a stable, lipidated long-acting amylin analogue selected through structure-activity relationship work (Kruse et al., J Med Chem 2021). See amylin glossary entry for background on the endogenous hormone.
Lyophilized peptides: Both cagrilintide and semaglutide research-grade materials are typically supplied lyophilized. Store at –20°C or –80°C until reconstitution. Avoid repeated freeze-thaw cycles. Reconstitute with an appropriate diluent per institutional protocol. Reconstituted solutions should be stored at 2–8°C and used within the timeframe specified by the supplier or validated by the laboratory.
Amylin analogue stability considerations: Cagrilintide was engineered to resist fibril formation, but amylin-based peptides may still aggregate under suboptimal storage conditions. Maintain recommended temperatures and pH ranges. For detailed storage protocols, see peptide storage guide.
COA verification: Laboratories sourcing research-grade cagrilintide or semaglutide should verify batch identity (mass spectrometry, HPLC retention time), purity, and endotoxin levels (LAL assay) via certificates of analysis before use. Sequence confirmation and molecular weight verification are critical for peptides with complex post-translational modifications or acylation. See how to read a peptide COA for step-by-step guidance.
When to consider semaglutide: Studies requiring an FDA-approved GLP-1 receptor agonist comparator, research on incretin signaling, or protocols benchmarking against established clinical data from the STEP and SUSTAIN programs. Semaglutide provides a well-characterized reference for GLP-1 pathway research. Research-grade semaglutide is available through multiple suppliers with documented COAs.
When to consider cagrilintide: Amylin receptor pathway research, studies modeling co-agonism of amylin and GLP-1 receptors, or alignment with the CagriSema development program. Cagrilintide offers a mechanism distinct from GLP-1 agonism and complements incretin-based therapies. Cagrilintide cannot be compounded in the U.S.; procurement must be limited to specialized research suppliers for institutional use. Verify regulatory compliance and institutional review board approval before sourcing.
When to consider the combination: Research protocols investigating dual amylin/GLP-1 receptor activation. The CagriSema phase 1b, phase 2, and phase 3 data provide a reference dataset for glycemic control and safety. Laboratories designing multi-peptide protocols should pair compound selection with specific assay endpoints, COA verification, and adherence to institutional guidelines for investigational agents.
Mechanistic orthogonality: Cagrilintide and semaglutide target distinct receptor systems—amylin receptor agonist versus GLP-1 receptor agonist—with complementary effects on satiety, gastric motility, and glucose homeostasis. In the phase 1b trial, cagrilintide exposure did not affect semaglutide exposure or elimination (Enebo et al., Lancet 2021).
Current research deal — use code SOL
10% off research peptides at Live Alpha Labs with code SOL. For research use only. We may earn from qualifying purchases.
Compound profile
Research overview
Related comparison
Related comparison
Dual agonist comparison
Pathway guide
Incretin cluster
Essential guide
Research use only
This comparison is for research reference. Cagrilintide is investigational and not FDA-approved. Semaglutide (Ozempic, Wegovy) is FDA-approved for type 2 diabetes and weight management; research-grade materials differ from pharmaceutical formulations. All content is for laboratory and analytical use only—not medical advice, not human dosing guidance. Institutional review board protocols and regulatory compliance required. Last reviewed November 16, 2026.
Cagrilintide is a long-acting amylin analogue that acts as an amylin receptor agonist, while semaglutide is a GLP-1 receptor agonist. They target different receptor systems: amylin receptors modulate satiety, gastric emptying, and glucagon suppression; GLP-1 receptors regulate insulin secretion, gastric emptying, and appetite. Both are once-weekly subcutaneous peptides with ~1 week half-lives, but they operate through distinct mechanisms.